Dark | Light
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

[Neurocrine Biosciences, Inc.](/topic/neurocrine-biosciences-inc)

### Sentiment: XXX%
![Sentiment Line Chart](https://lunarcrush.com/gi/w:600/t:neurocrine-biosciences-inc/c:line/m:sentiment/iv:1d.svg)  
[Sentiment 24-Hour Time-Series Raw Data](/topic/neurocrine-biosciences-inc/time-series/sentiment.tsv)  
**Current Value**: XXX%  
**Daily Average**: XX%  
**1 Week**: XXX% no change  
**1 Month**: XXX% +66%  
**6 Months**: XXX% +19%  
**1 Year**: XXX% +15%  
**1-Year High**: XXX% on 2025-07-20  
**1-Year Low**: XX% on 2025-09-23  

**Most Supportive Themes**
- **Strong Ingrezza Sales:** (40%) Ingrezza sales are increasing market penetration and revenue.
- **Positive Clinical Trial Data:** (35%) Positive outcomes from the Crenessity Phase X study boost confidence in Neurocrine's pipeline.
- **Affordable Growth Screen:** (25%) Mentions in 'Affordable Growth' screens highlight the potential for long-term value.
  
**Most Critical Themes**
- **Missed EPS Estimates:** (5%)  Missed EPS estimates may cause short-term volatility.
  
Network engagement breakdown:  
| Network | Positive | %  | Neutral | %  | Negative | %  |
| ------- | -------- | -  | ------- | -  | -------- | -  |
| Reddit  | X        | X% |         |    |          |    |
| X       | X        | X% | XXX     | X% | XX       | X% |
|         |          |    |         |    |          |    |
| Total   | XX       | X% | XXX     | X% | X        | X% |

[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

Neurocrine Biosciences, Inc.

Sentiment: XXX%

Sentiment Line Chart
Sentiment 24-Hour Time-Series Raw Data
Current Value: XXX%
Daily Average: XX%
1 Week: XXX% no change
1 Month: XXX% +66%
6 Months: XXX% +19%
1 Year: XXX% +15%
1-Year High: XXX% on 2025-07-20
1-Year Low: XX% on 2025-09-23

Most Supportive Themes

  • Strong Ingrezza Sales: (40%) Ingrezza sales are increasing market penetration and revenue.
  • Positive Clinical Trial Data: (35%) Positive outcomes from the Crenessity Phase X study boost confidence in Neurocrine's pipeline.
  • Affordable Growth Screen: (25%) Mentions in 'Affordable Growth' screens highlight the potential for long-term value.

Most Critical Themes

  • Missed EPS Estimates: (5%) Missed EPS estimates may cause short-term volatility.

Network engagement breakdown:

Network Positive % Neutral % Negative %
Reddit X X%
X X X% XXX X% XX X%
Total XX X% XXX X% X X%
Neurocrine Biosciences, Inc. (NBIX) Sentiment
/topic/neurocrine-biosciences-inc/sentiment